The DOI matches its Crossref record.
Countering the Problem of Falsified and Substandard Drugs
Abstract
The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today.The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Global health security: the wider lessons from the west African Ebola virus disease epidemic
Heymann, D. L., Chen, L., Takemi, K., Fidler, D. P., Tappero, J. W., Thomas, M. J., Kenyon, T. A., Frieden, T. R., Yach, D., Nishtar, S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60858-3 · Cited by 560
Hitching Healthcare to the Chain: An Introduction to Blockchain Technology in the Healthcare Sector
Engelhardt, M. A. (2017) · Technology Innovation Management Review · doi:10.22215/timreview/1111 · Cited by 390
Ozawa, S., Evans, D. R., Bessias, S., Haynie, D. G., Yemeke, T. T., Laing, S. K., & Herrington, J. E. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.1662 · Cited by 356
Gostin, L. O., Monahan, J. T., Kaldor, J., DeBartolo, M., Friedman, E. A., Gottschalk, K., Kim, S. C., Alwan, A., Binagwaho, A., Burci, G. L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30233-8 · Cited by 338
Yadav, P. (2015) · Health Systems & Reform · doi:10.4161/23288604.2014.968005 · Cited by 308
Substandard drugs: a potential crisis for public health
Johnston, A., & Holt, D. W. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12298 · Cited by 270
Performance of retail pharmacies in low- and middle-income Asian settings: a systematic review
Miller, R., & Goodman, C. (2016) · Health Policy and Planning · doi:10.1093/heapol/czw007 · Cited by 225
Seidman, G., & Atun, R. (2017) · BMJ Global Health · doi:10.1136/bmjgh-2016-000243 · Cited by 133
Revisiting the issue of access to medicines in Africa: Challenges and recommendations
Adebisi, Y. A., Nwogu, I. B., Alaran, A. J., Badmos, A. O., Bamgboye, A. O., Rufai, B. O., Okonji, O. C., Malik, M. O., Teibo, J. O., Abdalla, S. F., et al. (2022) · Public Health Challenges · doi:10.1002/puh2.9 · Cited by 111
Treating Severe Malaria in Pregnancy: A Review of the Evidence
Kovacs, S. D., Rijken, M. J., & Stergachis, A. (2015) · Drug Safety · doi:10.1007/s40264-014-0261-9 · Cited by 66
Ethical challenges in designing and conducting medicine quality surveys
Tabernero, P., Parker, M., Ravinetto, R., Phanouvong, S., Yeung, S., Kitutu, F. E., Cheah, P. Y., Mayxay, M., Guerin, P. J., & Newton, P. N. (2016) · Tropical Medicine & International Health · doi:10.1111/tmi.12707 · Cited by 20
Metadata
- Authors
- Committee on Understanding the Global Public Health Implications of Substandard, F., Board on Global Health, & Institute of Medicine
- Venue
- National Academies Press eBooks
- Publisher
- National Academies Press
- Published
- 2013-05-20
- OpenAlex
- W1668247097
- Cited by
- 209
- References
- 0
- FWCI
- 25.95
- Type
- book
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.